AI Article Synopsis
- The study aimed to evaluate the effectiveness of cenegermin-bkbj in treating neurotrophic keratitis (NK) while using a bandage contact lens (BCL).
- Researchers reviewed patient charts from 2018 to 2020, focusing on visual acuity, corneal sensation before and after treatment, and treatment results.
- Results showed significant improvements in corneal sensation and reduction of epithelial defects, indicating that maintaining BCL use during cenegermin-bkbj treatment may benefit patients with NK.
Article Abstract
Purpose: The aim of this study was to characterize the outcomes of eyes with neurotrophic keratitis (NK) treated with a course of cenegermin-bkbj in the presence of a bandage contact lens (BCL).
Methods: A retrospective chart review of all eyes with a clinical diagnosis of NK treated with cenegermin-bkbj was performed between 2018 and 2020. Inclusion criteria included cenegermin-bkbj treatment with a BCL in place. Demographics, etiology, visual acuity, pretreatment and posttreatment corneal sensation, and treatment outcomes were assessed.
Results: There were 18 eyes of 16 patients (69% female) with NK treated with cenegermin-bkbj while having a BCL in place. After cenegermin-bkbj treatment, presence of corneal sensation significantly increased from 7% of eyes to 79% of eyes (P < 0.0001). There was also a significant increase in the number of quadrants with corneal sensation (mean of 0.1 quadrants increased to 1.6 quadrants, P =0.0005). Six of 10 eyes (67%; P = 0.004) with a persistent epithelial defect (PED) experienced complete resolution at the conclusion of treatment, while 3 additional eyes experienced a decrease in the defect size. Despite all 18 eyes necessitating a chronic BCL before cenegermin-bkbj treatment, 4 were able to maintain their epithelium without a BCL after treatment for at least some period.
Conclusions: Cenegermin-bkbj treatment for NK with a BCL in place demonstrated improvement in corneal sensation, epithelial defect size, and fluorescein staining. In eyes demonstrating previous ocular surface decompensation with discontinuation of a BCL, maintenance of BCL use during treatment with cenegermin-bkbj may be considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICO.0000000000002797 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Delivery in PROSE Device as Alternative to Frequent Drop Administration in Severe Ocular Surface Disease.
Eye Contact Lens
December 2024
Department of Ophthalmology, Massachusetts Eye & Ear, Harvard University, Boston, MA.
The design of the prosthetic replacement of the ocular surface ecosystem (PROSE) device allows it to serve as a novel drug delivery system. In this article, we describe the off-label administration of amphotericin B and cenegermin by instillation in the PROSE device reservoir for the treatment of Candida keratitis in the setting of a persistent epithelial defect.
View Article and Find Full Text PDFNerve Growth Factor Treatment for Neurotrophic Keratopathy in the IRIS® Registry.
Ophthalmology
November 2024
Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Quintessence of currently approved and upcoming treatments for dry eye disease.
Graefes Arch Clin Exp Ophthalmol
August 2024
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, near Khalsa College, Matunga East, Mumbai, 400019, India.
Article Synopsis
- - Dry eye disease (DED) is a complex eye condition, and this review summarizes current and future treatment options for it by looking at research from PubMed, FDA, and other databases.
- - Current FDA-approved treatments for DED include several cyclosporine formulations, lifitegrast (XIIDRA), and various medical devices designed to improve tear production and treat meibomian gland dysfunction.
- - Numerous clinical trials are ongoing to evaluate new treatments for DED, including various novel drops and solutions, aiming to enhance symptomatic relief as well as overall management of the disease.
The use of rh-NGF in the management of neurotrophic keratopathy.
Front Ophthalmol (Lausanne)
July 2024
Ophthalmology Department, Miguel Hernandez University, Alicante, Spain.
Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and systemic condition associated with the disease and ocular surface and corneal sensitivity examinations.
View Article and Find Full Text PDFRecombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.
BMC Ophthalmol
July 2024
Dompé farmaceutici S.p.A, Via Santa Lucia 6, Milan, 20122, Italy.
Background: Dry eye disease (DED) includes neurosensory abnormalities as part of its multifactorial etiology. Nerve growth factor is important for maintaining corneal nerve integrity and wound healing. Cenegermin (recombinant human nerve growth factor) is a topical biologic that promotes corneal healing in patients with neurotrophic keratitis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!